Type 2 Biomarkers and Their Clinical Implications in Bronchiectasis: A Prospective Cohort Study

Area of Science:

• Pulmonology and Respiratory Medicine
• Clinical Immunology
• Biomarker Research

Background:

• Bronchiectasis is characterized by neutrophilic inflammation, but the role of type 2 biomarkers in disease severity and exacerbation risk remains unclear.
• Understanding these biomarkers is crucial for improving patient management strategies in bronchiectasis.

Purpose of the Study:

• To investigate the clinical significance of type 2 biomarkers, including blood eosinophil count (BEC), serum total immunoglobulin E (IgE), and fractional exhaled nitric oxide (FeNO), in patients with bronchiectasis.
• To assess the association of these biomarkers with disease severity and exacerbation risk.

Main Methods:

• A cross-sectional cohort study was conducted on 130 bronchiectasis patients (excluding asthma or allergic bronchopulmonary aspergillosis).
• Clinical and radiological evaluations were performed, alongside bronchoalveolar lavage analysis for cytokines and microbiology.
• Type 2 biomarkers (BEC, serum total IgE, FeNO) were measured during stable disease states, with positive thresholds defined by established criteria.

Main Results:

• Approximately 60% of patients had at least one positive type 2 biomarker (BEC ≥300 cells/μL, FeNO ≥25 ppb, or IgE ≥75 kU/L).
• BEC and FeNO showed variable impacts on clinical characteristics and disease severity, reflecting different aspects of the disease.
• Pseudomonas aeruginosa colonization and a high neutrophil-to-lymphocyte ratio (NLR ≥3.0) were more significant predictors of exacerbation frequency than type 2 biomarkers.

Conclusions:

• Type 2 biomarkers, particularly BEC and FeNO, play distinct roles in assessing bronchiectasis severity and predicting exacerbation risk.
• A multi-biomarker strategy, integrating type 2 biomarkers with microbiological and clinical assessments, is recommended for comprehensive bronchiectasis management.